Shares of Shield Therapeutics plc (LON:STX – Get Free Report) fell 2.7% on Wednesday . The stock traded as low as GBX 2.70 ($0.03) and last traded at GBX 2.75 ($0.04). 2,423,015 shares were traded during trading, a decline of 47% from the average session volume of 4,531,060 shares. The stock had previously closed at GBX 2.83 ($0.04).
Shield Therapeutics Trading Down 2.7 %
The business’s 50-day simple moving average is GBX 3.36 and its two-hundred day simple moving average is GBX 3.09. The firm has a market capitalization of £21.51 million, a price-to-earnings ratio of -68.75 and a beta of 1.42. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50.
About Shield Therapeutics
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Further Reading
- Five stocks we like better than Shield Therapeutics
- What is a buyback in stocks? A comprehensive guide for investors
- The Great CPU Race: AMD and Intel Battle for Dominance
- What is the Nikkei 225 index?
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- P/E Ratio Calculation: How to Assess Stocks
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
